本帖最后由 老马 于 2012-1-13 21:20 编辑 ; y# z' H/ d' O$ U5 o& H
5 n h& f/ J, ^爱必妥和阿瓦斯丁的比较
$ Z% `2 R8 e& Q% v4 V' k7 P
6 q: g7 @" j3 H _+ W2 g0 z
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/5 A% W+ i/ {& G! f5 _0 h* h
; |. G/ G. a, ^# p
0 |- M, |# X( j: M# G* l0 h9 ?
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
4 Q" \; [# e! Z4 F* a==================================================7 C0 f7 ?% d& W
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)6 I! H6 b" f( i1 \
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
7 [( V( c; d* j$ @% P4 kResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.' z; R& H4 s& h& T: ]+ W8 z2 D
|